JPH02233680A - ５ｈｔ↓２受容体の選択的遮断剤 - Google Patents

５ｈｔ↓２受容体の選択的遮断剤

Info

Publication number
JPH02233680A
JPH02233680A JP2007010A JP701090A JPH02233680A JP H02233680 A JPH02233680 A JP H02233680A JP 2007010 A JP2007010 A JP 2007010A JP 701090 A JP701090 A JP 701090A JP H02233680 A JPH02233680 A JP H02233680A
Authority
JP
Japan
Prior art keywords
acid
serotonin
therapeutic agent
pharmaceutically acceptable
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007010A
Other languages
English (en)
Japanese (ja)
Inventor
Marlene L Cohen
マーレン・ロイス・コーエン
Mark J Goldberg
マーク・ジェイ・ゴールドバーグ
Louis Lemberger
ルイス・レンバーガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH02233680A publication Critical patent/JPH02233680A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sorption Type Refrigeration Machines (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007010A 1989-01-17 1990-01-16 ５ｈｔ↓２受容体の選択的遮断剤 Pending JPH02233680A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/297,208 US4914107A (en) 1989-01-17 1989-01-17 Method for selectively blocking 5-HT2 receptors
US297208 1994-08-29

Publications (1)

Publication Number Publication Date
JPH02233680A true JPH02233680A (ja) 1990-09-17

Family

ID=23145320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007010A Pending JPH02233680A (ja) 1989-01-17 1990-01-16 ５ｈｔ↓２受容体の選択的遮断剤

Country Status (9)

Country Link
US (1) US4914107A (enExample)
EP (1) EP0379308B1 (enExample)
JP (1) JPH02233680A (enExample)
AT (1) ATE79539T1 (enExample)
CA (1) CA2007472A1 (enExample)
DE (1) DE69000259T2 (enExample)
DK (1) DK0379308T3 (enExample)
ES (1) ES2044422T3 (enExample)
GR (1) GR3005963T3 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212860T1 (de) * 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933082A (en) * 1960-10-06 1963-08-08 Sandoz Ag Improvements in or relating to lysergic acid derivatives
US3580916A (en) * 1969-02-20 1971-05-25 Lilly Co Eli Hydroxyesters of hexa- and octahydroindoloquinolines
SE396753B (sv) * 1970-05-18 1977-10-03 Richter Gedeon Vegyeszet Analogiforfarande for framstellning av en forening tillhorande dihydrolysergsyraserien
DE2330912C3 (de) * 1972-06-22 1979-01-11 Societa Farmaceutici Italia S.P.A., Mailand (Italien) Verfahren zur Herstellung von Bromergolinverbindungen
DE3207775A1 (de) * 1981-03-13 1982-09-23 Sandoz-Patent-GmbH, 7850 Lörrach Verfahren zur herstellung von mutterkornalkaloiden
US4713384A (en) * 1985-10-01 1987-12-15 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4714704A (en) * 1985-10-01 1987-12-22 Eli Lilly And Company Alkoxy cycloalkanol esters of dihydrolysergic acid useful as 5HT receptor antagonists
US4734501A (en) * 1985-10-01 1988-03-29 Eli Lilly And Company N-alkylation of dihydrolysergic acid

Also Published As

Publication number Publication date
ATE79539T1 (de) 1992-09-15
DE69000259D1 (de) 1992-09-24
DK0379308T3 (da) 1992-09-28
US4914107A (en) 1990-04-03
DE69000259T2 (de) 1993-03-11
EP0379308B1 (en) 1992-08-19
GR3005963T3 (enExample) 1993-06-07
EP0379308A1 (en) 1990-07-25
ES2044422T3 (es) 1994-01-01
CA2007472A1 (en) 1990-07-17

Similar Documents

Publication Publication Date Title
US4563461A (en) Selective method for blocking 5HT2 receptors
MacCarthy et al. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects
SK11596A3 (en) A composition for the therapy of undepressed women suffer from hypothalamic amenorrhea
TWI302100B (en) Composition for treating drug-induced constipation
SK287972B6 (sk) Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof
HU190699B (en) Process for producing analgesic composition containing nalbufin
CA2722845A1 (en) Pharmaceutical composition for the treatment of premature ejaculation
US4713384A (en) Selective method for blocking 5HT2 receptors
KR0163840B1 (ko) (r)-암로디핀에 의한 평활근 세포 이동의 억제
US4468401A (en) Method of blocking peripheral norepinephrine release
JPH07502528A (ja) 膀胱疾患の治療薬を製造するための５−ｈｔ↓４モジュレーターの使用
US4762842A (en) Selective method for blocking 5HT2 receptors
US4914107A (en) Method for selectively blocking 5-HT2 receptors
EP0738513A1 (en) Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
JPS6348217A (ja) 麻酔薬組成物
Muravchick et al. Glycopyrrolate and cardiac dysrhythmias in geriatric patients after reversal of neuromuscular blockade
US4810710A (en) 4-hydroxycyclohexyl 1-isopropyl-9,10-dihydro-lysergate for the treatment of migraine
US4520024A (en) Method of selectively blocking peripheral vascular serotonergic receptors
EP0310259B1 (en) Eperisone as a hypotensive agent
US4012525A (en) Novel propoxyphene dosage regimen
US20030087938A1 (en) Treatment of chronic pain with 3-heterocycloxy-and 3-cycloalkyloxy-3-phenylpropanamines
Roath Management of Raynaud’s phenomenon: focus on newer treatments
JPH02157224A (ja) １―ジフェニルメチル―４―［（２―（４―メチルフェニル）―５―メチル―１ｈ―イミダゾール―４―イル）メチル］ピペラジン非経口製剤
Cohen et al. Comparative 5‐HT2‐Receptor Antagonist Activity of Amesergide and its Active Metabolite 4‐Hydroxyamesergide in Rats and Rabbits
US6121328A (en) Racemic propranolol